Rosuvastatin

• Description:

  Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[1][2][3].

• Product Name Alternative:

  ZD 4522

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Autophagy; Bacterial; HMG-CoA Reductase (HMGCR) ; Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Metabolic Disease; Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/rosuvastatin.html

• Purity:

  99.67

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C(O)C[C@H](O)C[C@H](O)/C=C/C1=C(C(C)C)N=C(N(C)S(=O)(C)=O)N=C1C2=CC=C(F)C=C2

• Molecular Formula:

  C22H28FN3O6S

• Molecular Weight:

  481.54

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5 (2) : p. 437-44.|[2]Plante I, et al. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012 Feb;101 (2) :868-78.|[3]Feng PF, et al. Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane. Mol Pharm. 2019 Apr 1;16 (4) :1477-1488.|[4]Carswell C.I., et al. Rosuvastatin. Drugs, 2002. 62 (14) : p. 2075-85; discussion 2086-7.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  ACS Omega. 2025 Oct 29;10 (44) :52562–52575.|Biomed Pharmacother. 2025 Oct 21:192:118665.|Biosens Bioelectron. 2025 Nov 15:288:117807.|Eur J Pharmacol. 2023 Sep 15:955:175911.|Exp Ther Med. 2021 Oct;22 (4) :1189.|Front Cell Dev Biol. 2021 May 6;9:651579.|Front Oncol. 2021 May 10:11:595285.|J Inflamm Res. 2021 Apr 16:14:1537-1549.|J Nephropharmacol. 2025 Sep 20:e12798|Phytomedicine. 2024 Apr 10, 155621.|Vasc Endovasc Rev. 2025 Nov 7.|World J Methodol. 2025 Jun 20;15 (2) :99580.|Acta Pharmacol Sin. 2023 Jul;44 (7) :1416-1428.|Adv Sci (Weinh) . 2024 Jul 5:e2403451.|bioRxiv. 2024 November 08.|Cell Death Discov. 2024 May 29;10 (1) :263.|Cell Metab. 2025 Sep 2;37 (9) :1907-1925.e14.|Cell Signal. 2025 Jul:131:111753.|Front Bioeng Biotechnol. 2022 Mar 17;10:826093.|Front Cell Dev Biol. 2022 Mar 3;10:806081.|MedComm (2020) . 2024 Aug 31;5 (9) :e681.|Pharm Res. 2025 Oct 27.|Phytomedicine. 2025 Jun 19:145:157014.

• CAS Number:

  [287714-41-4]